| Literature DB >> 33609917 |
Maedeh Sherafati1, Roghieh Mirzazadeh2, Ebrahim Barzegari3, Maryam Mohammadi-Khanaposhtani4, Homa Azizian5, Mohammad Sadegh Asgari6, Samanesadat Hosseini7, Ebrahim Zabihi4, Somayeh Mojtabavi8, Mohammad Ali Faramarzi8, Mohammad Mahdavi9, Bagher Larijani1, Hossein Rastegar10, Haleh Hamedifar11, Mir Hamed Hajimiri12.
Abstract
A series of new quinazolinone-dihydropyrano[3,2-b]pyran derivatives 10A-L were synthesized by simple chemical reactions and were investigated for inhibitory activities against α-glucosidase and α-amylase. New synthesized compounds showed high α-glucosidase inhibition effects in comparison to the standard drug acarbose and were inactive against α-amylase. Among them, the most potent compound was compound 10L (IC50 value = 40.1 ± 0.6 µM) with inhibitory activity around 18.75-fold more than acarboase (IC50 value = 750.0 ± 12.5 µM). This compound was a competitive inhibitor into α-glucosidase. Our obtained experimental results were confirmed by docking studies. Furthermore, the cytotoxicity of the most potent compounds 10L, 10G, and 10N against normal fibroblast cells and in silico druglikeness, ADME, and toxicity prediction of these compounds were also evaluated.Entities:
Keywords: Docking study; Pharmacokinetic prediction; Quinazolinone-dihydropyrano[3,2-b]pyran hybrids; Type 2 diabetes; α-Amylase; α-Glucosidase
Year: 2021 PMID: 33609917 DOI: 10.1016/j.bioorg.2021.104703
Source DB: PubMed Journal: Bioorg Chem ISSN: 0045-2068 Impact factor: 5.275